Article
Medicine, Research & Experimental
Cancan Lyu, Yuanchao Ye, Maddison M. Lensing, Kay-Uwe Wagner, Ronald J. Weigel, Songhai Chen
Summary: In HER2(+) breast cancer, overactivation of HER2 leads to aberrant G(i/o)-GPCR signaling, promoting cancer progression and resistance to HER2-targeted therapy. Pharmacologically deactivating GPCR signaling can block tumor growth and enhance therapeutic efficacy.
Article
Medicine, General & Internal
Nuria Chic, Francesco Schettini, Fara Braso-Maristany, Esther Sanfeliu, Barbara Adamo, Maria Vidal, Debora Martinez, Patricia Galvan, Blanca Gonzalez-Farre, Javier Cortes, Joaquin Gavila, Cristina Saura, Mafalda Oliveira, Sonia Pernas, Olga Martinez-Saez, Jesus Soberino, Eva Ciruelos, Lisa A. Carey, Montserrat Munoz, Charles M. Perou, Tomas Pascual, Meritxell Bellet, Aleix Prat
Summary: Chemotherapy has different biological effects on patients with hormone receptor-positive breast cancer with different menopausal statuses. Specific estrogen-regulated genes exhibited varied expression levels under different treatment regimens in these patients.
Article
Biochemistry & Molecular Biology
Noelia Miret, Lorena Zarate, Fernando Erra Diaz, M. Agustina Leguizamon, Carolina A. Pontillo, Florencia A. Chiappini, Leandro Ceballos, Jorge Geffner, Andrea S. Randi
Summary: A reduction in extracellular pH promotes breast cancer progression by activating the AhR/c-Src axis, which increases cell migration and MMP-9 activity.
JOURNAL OF CELLULAR BIOCHEMISTRY
(2022)
Editorial Material
Oncology
Alicia F. C. Okines, Nicholas C. Turner
Summary: HER2 amplification heterogeneity is linked to resistance to trastuzumab emtansine in the neoadjuvant setting, highlighting the significance of determining whether varying HER2-positive cancer types require distinct treatment approaches.
Article
Multidisciplinary Sciences
Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri, Svasti Haricharan
Summary: Resistance to endocrine treatment in ER+ breast cancer patients is linked to activation of HER2 due to loss of mismatch repair, and inhibiting HER2 restores sensitivity to treatment. Loss of MutL and upregulation of HER2 are associated with sensitivity to HER inhibitors in ER+/HER2(-) patients.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Hana Dostalova, Radek Jorda, Eva Reznickova, Vladimir Krystof
Summary: Small molecule Bruton's tyrosine kinase (BTK) inhibitors, including ibrutinib, have shown potential as effective treatments for haemato-oncological diseases. Recent studies have identified HER2 as an off-target kinase of BTK inhibitors, suggesting that these drugs may be repurposed for HER2-positive breast cancer. In this study, we investigated the anticancer effects of zanubrutinib, evobrutinib, tirabrutinib and acalabrutinib in different BCa cell lines and found that zanubrutinib effectively inhibits the HER2 signalling pathway and reduces cell proliferation. These findings support the potential use of zanubrutinib in HER2-amplified solid tumours.
INVESTIGATIONAL NEW DRUGS
(2023)
Article
Oncology
Daeun You, Hyungjoo Kim, Yisun Jeong, Sun Young Yoon, Eunji LO, Jeong Eon Lee, Sangmin Kim
Summary: This study investigated the regulatory mechanism of CCL2 expression in HER2-positive breast cancer. The results showed that HER2 overexpression increased CCL2 expression, which was regulated through the EGFR/Src-dependent signaling.
ANTICANCER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Thidarath Rattanaburee, Tanotnon Tanawattanasuntorn, Tienthong Thongpanchang, Varomyalin Tipmanee, Potchanapond Graidist
Summary: The study demonstrated that trans-(+/-)-kusunokinin may bind HER2 with low affinity in breast cancer cells, and exhibited a different action compared to neratinib. In cell experiments, (+/-)-kusunokinin showed lower cytotoxicity on normal cells and stronger inhibition of cell proliferation than siRNA-HER2.
Article
Multidisciplinary Sciences
Yutian Zou, Shaoquan Zheng, Xinhua Xie, Feng Ye, Xiaoqian Hu, Zhi Tian, Shu-Mei Yan, Lu Yang, Yanan Kong, Yuhui Tang, Wenwen Tian, Jindong Xie, Xinpei Deng, Yan Zeng, Zhe-Sheng Chen, Hailin Tang, Xiaoming Xie
Summary: FGFR4 inhibition enhances sensitivity to anti-HER2 treatment in resistant breast cancer cells by triggering ferroptosis.
NATURE COMMUNICATIONS
(2022)
Article
Chemistry, Analytical
Qiaohong Lin, Pengyun Li, Mengxuan Fang, Donghui Zhang, Yu Xia
Summary: A new LC-MS workflow was developed for deep profiling of PEs, ether-PEs, and PSs in mammalian cell membranes. Integration of two orthogonal derivatizations significantly improved the limit of identification for PSs and ether-PEs, allowing the discovery of over 200 molecular species in the porcine brain, double that of previous identifications without TMAB-NHS derivatization. Furthermore, the study revealed potential mechanisms of lipid reprogramming in cancer cells through the formation of different C=C location isomers.
ANALYTICAL CHEMISTRY
(2022)
Review
Oncology
Diogo Martins-Branco, Guilherme Nader-Marta, Chiara Molinelli, Lieveke Ameye, Marianne Paesmans, Michail Ignatiadis, Philippe Aftimos, Roberto Salgado, Evandro de Azambuja
Summary: High Ki-67 index is associated with worse survival outcomes in women with ER-positive/HER2-negative early breast cancer.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Pharmacology & Pharmacy
Noelia Miret, Carolina A. Pontillo, Sol Bujan, Florencia A. Chiappini, Andrea S. Randi
Summary: This literature review addresses the role of the aryl hydrocarbon receptor (AhR) and its ligands in breast cancer. The study explores the biological mechanisms of AhR agonists in interfering with breast endocrine functions and their impact on breast cancer development and progression. The findings suggest that exposure to AhR agonists stimulates pathways that promote breast cancer and contribute to tumor progression. Therefore, the evaluation and regulation of industrial and agricultural chemicals and other toxicants are essential in reducing the risk of breast cancer.
BIOCHEMICAL PHARMACOLOGY
(2023)
Article
Cell Biology
Soon Young Park, Kang Jin Jeong, Alfonso Poire, Dong Zhang, Yiu Huen Tsang, Aurora S. Blucher, Gordon B. Mills
Summary: Ferroptosis, a type of programmed cell death, can be enhanced by inhibiting the xCT transporter or GPX4. In luminal breast cancer, GPX4 levels are selectively elevated, while xCT transporter levels remain unchanged. Luminal breast cancer cell lines are more sensitive to RSL3, which activates HER2 pathway, compared to erastin. Combination treatment of RSL3 and neratinib, an irreversible HER2 inhibitor, increases ferroptosis through mitochondrial iron-dependent reactive oxygen species production and lipid peroxidation. These findings suggest that clinical trials combining RSL3 and irreversible HER2 inhibitors should be explored.
CELL DEATH & DISEASE
(2023)
Article
Biochemistry & Molecular Biology
Yayun Gu, Huanyao Gao, Huan Zhang, August John, Xiujuan Zhu, Suganti Shivaram, Jia Yu, Richard M. Weinshilboum, Liewei Wang
Summary: The TRAF4-SMURF2 complex is identified as a potential mechanism for maintaining HER2 signaling in HER2-positive breast cancer cells during Trastuzumab treatment. Knockdown of TRAF4 reduces HER2 stability and improves Trastuzumab sensitivity.
Article
Multidisciplinary Sciences
Anna Adam-Artigues, Enrique J. Arenas, Alex Martinez-Sabadell, Fara Braso-Maristany, Raimundo Cervera, Eduardo Tormo, Cristina Hernando, Maria Teresa Martinez, Juan Carbonell-Asins, Soraya Simon, Jesus Poveda, Santiago Moragon, Sandra Zazo, Debora Martinez, Ana Rovira, Octavio Burgues, Federico Rojo, Joan Albanell, Begona Bermejo, Ana Lluch, Aleix Prat, Joaquin Arribas, Pilar Eroles, Juan Miguel Cejalvo
Summary: AXL overexpression is identified as an essential mechanism of trastuzumab resistance in HER2-positive breast cancer, and targeting AXL can restore trastuzumab response. AXL may serve as a predictive biomarker for prognosis in HER2-positive breast cancer patients. The study emphasizes the importance of targeting AXL in combination with anti-HER2 drugs to overcome resistance.
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)